Prescription Required
Inclusive of all taxes
In Osteoporosis Osteoporosis is a common condition that weakens bones, making them fragile and more likely to break. It often occurs in women after menopause. This condition can be treated with bone-strengthening medicines. Xgeva Solution for Injection slows down the rate at which bone is broken down in your body. This maintains bone density and reduces your risk of breaking a bone. The injection is given by a doctor or nurse and should not be self-administered. You can help improve the strength of your bones by doing regular exercise (especially weight-bearing exercise), eating healthy foods containing calcium and Vitamin D and reducing your consumption of alcohol and tobacco. Supplements of calcium and Vitamin D3 are also effective.
Caution is advised when consuming alcohol with Xgeva Solution for Injection. Please consult your doctor.
Xgeva Solution for Injection is highly unsafe to use during pregnancy. Seek your doctor's advice as studies on pregnant women and animals have shown significant harmful effects to the developing baby.
Xgeva Solution for Injection is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Xgeva Solution for Injection does not usually affect your ability to drive.
Xgeva Solution for Injection is safe to use in patients with kidney disease. No dose adjustment of Xgeva Solution for Injection is recommended.
Xgeva Solution for Injection is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Xgeva Solution for Injection may not be needed in these patients. Please consult your doctor.
If you miss a dose of Xgeva Solution for Injection, please consult your doctor.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More
Marketer/Manufacturer: Reliance Life Sciences || ₹14.5/tablet (25% cheaper)